JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2.

THE JAPAN SOCIETY of Hepatology and Drafting Committee for Hepatitis Management Guidelines produced the first clinical practice guidelines for the management of hepatitis C virus (HCV) infection in 2012, followed by frequent updates. As English versions, we published JSH guidelines in 2013, and a 2014 update for genotype 1 in 2014. Thereafter several interferon-free regimens with direct acting antivirals (DAAs) have been launched in the clinical setting both for genotype 1 and 2 and treatment recommendations have been greatly changed with these progresses. In this year 2016, the Drafting Committee for Hepatitis Management Guidelines lauched a 2016 update for genotype 1 and 2. These JSH guidelines are intended to assist physicians and other healthcare providers to assist their decision making in the clinical process. The Committee defenitely hope these guideline help patients infected with HCV, their families and other interested individuals to overcome HCV infection and improve the outcome and quality of life with assistance of physicians and other healthcare providers. In these updated version, we focused on newly-available IFN-free DAAs and the current treatment recommendations. Please refer to the previous versions when IFN, ribavirin, and other IFN-based DAAs (telaprevir, simeprevir) are of interst. Correspondence: Atsushi Tanaka, Department of Medicine, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo 173-8605. Email: [email protected] Conflicts of Interest: Conflicts of interest of the “Hepatitis C Treatment Guidelines (Third Version)”Hepatitis Treatment Guideline Preparation Committee Members 1 Financial compensation (1,000,000 yen or more per year from a single company/organization) None 2 Profits from shares (1,000,000 yen or more, or 5% or more of said shares, per year from a single company)No stock owned 3 Patent use fees (1,000,000 yen or more per year for a single patent) SRL Inc. 4 Speaking fees (1,000,000 yen or more per year from a single company or organization) MSD, Dainippon Sumitomo Pharma Company, Ltd., Bristol-Myers K.K., Mitsubishi Tanabe Pharma Corporation, Toray Industries, Janssen Pharmaceutica, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd. 5 Manuscript fees (1,000,000 yen or more per year from a single company or organization) None 6 Total amount of research fees, grants, etc. (2,000,000 yen or more per year total paid from affiliated departments in a single company or organization sharing research expenses (e.g., courses, fields, or laboratories)) None *Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology (in alphabetical order):Yasuhiro Asahina, Department of Gastroenterology and Hepatology, School of Medicine, Tokyo Medical and Dental University; Namiki Izumi, Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital; Kumada Hiromitsu, Department of Hepatology, Toranomon Hospital; Masayuki Kurosaki, Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital; **Kazuhiko Koike, Department ofGastroenterology, Graduate School of Medicine, The University of Tokyo; Fumitaka Suzuki, Department of Hepatology, Toranomon Hospital; * Hajime Takikawa, Department of Medicine, Teikyo University School of Medicine; Atsushi Tanaka, Department of Medicine, Teikyo University School of Medicine; Eiji Tanaka, The Second Department of Internal Medicine, ShinshuUniversity School ofMedicine; Yasuhito Tanaka, Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Science;Hirohito Tsubouchi, KagoshimaCityHospital, Norio Hayashi, Kansai-Rosai Hospital; Naoki Hiramatsu, Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine; Hiroshi Yotsuyanagi, Department of Infectious Diseases, Graduate School of Medicine, The University of Tokyo (* Committee chair; ** Special committee member) 7 Total amount of scholarship (support) payments received (2,000,000 yen or more per year paid by affiliated departments (e.g., courses, fields, laboratories) in a single company or organization sharing a scholarship budget) MSD, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Pharmaceutical Co., Ltd. 8 Sponsored courses provided by companies, etc. (noted when there is an affiliation with a course sponsored by a company, etc.) MSD, Dainippon Sumitomo Pharma Company, Ltd., Bristol-Myers, K.K., Toray Industries, Chugai Pharmaceutical Co., Ltd. 9 Receipt of travel expenses, gifts, etc. (50,000 yen or more per year from a single company or organization) None